MX2016012176A - Composiciones y metodos para mejorar los linfocitos infiltrantes de tumor para terapia celular adoptiva. - Google Patents

Composiciones y metodos para mejorar los linfocitos infiltrantes de tumor para terapia celular adoptiva.

Info

Publication number
MX2016012176A
MX2016012176A MX2016012176A MX2016012176A MX2016012176A MX 2016012176 A MX2016012176 A MX 2016012176A MX 2016012176 A MX2016012176 A MX 2016012176A MX 2016012176 A MX2016012176 A MX 2016012176A MX 2016012176 A MX2016012176 A MX 2016012176A
Authority
MX
Mexico
Prior art keywords
tumor
cell therapy
adoptive cell
infiltrating lymphocytes
disclosed
Prior art date
Application number
MX2016012176A
Other languages
English (en)
Inventor
A Sarnaik Amod
Pilon-Thomas Shari
Mclaughlin Mark
Liu Hao
Original Assignee
H Lee Moffitt Cancer Ct & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lee Moffitt Cancer Ct & Res filed Critical H Lee Moffitt Cancer Ct & Res
Publication of MX2016012176A publication Critical patent/MX2016012176A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/056—Immunostimulating oligonucleotides, e.g. CpG
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)

Abstract

Se describen composiciones y métodos para la expansión ex vivo de linfocitos infiltrantes de tumor para usar en la terapia celular adoptiva (ACT). También se describen composiciones y métodos para identificar un agente para la expansión ex vivo de linfocitos infiltrantes de tumor para usar en la ACT. También se describen métodos para el tratamiento del cáncer usando linfocitos infiltrantes de tumor expandidos mediante los métodos descritos.
MX2016012176A 2014-03-20 2015-03-20 Composiciones y metodos para mejorar los linfocitos infiltrantes de tumor para terapia celular adoptiva. MX2016012176A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461955970P 2014-03-20 2014-03-20
US201461973002P 2014-03-31 2014-03-31
PCT/US2015/021759 WO2015143328A1 (en) 2014-03-20 2015-03-20 Tumor-infiltrating lymphocytes for adoptive cell therapy

Publications (1)

Publication Number Publication Date
MX2016012176A true MX2016012176A (es) 2017-04-13

Family

ID=54145388

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016012176A MX2016012176A (es) 2014-03-20 2015-03-20 Composiciones y metodos para mejorar los linfocitos infiltrantes de tumor para terapia celular adoptiva.
MX2020005634A MX2020005634A (es) 2014-03-20 2016-09-20 Composiciones y metodos para mejorar los linfocitos infiltrantes de tumor para terapia celular adoptiva.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020005634A MX2020005634A (es) 2014-03-20 2016-09-20 Composiciones y metodos para mejorar los linfocitos infiltrantes de tumor para terapia celular adoptiva.

Country Status (11)

Country Link
US (3) US20170081635A1 (es)
EP (2) EP3698850A1 (es)
JP (3) JP2017511375A (es)
KR (2) KR20230085225A (es)
CN (2) CN106659913A (es)
AU (3) AU2015231041B2 (es)
CA (1) CA2943389C (es)
EA (1) EA036386B1 (es)
ES (1) ES2776407T3 (es)
MX (2) MX2016012176A (es)
WO (1) WO2015143328A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106659913A (zh) * 2014-03-20 2017-05-10 H.李莫菲特癌症中心研究院 用于过继细胞疗法的肿瘤浸润淋巴细胞
US20170044496A1 (en) 2014-04-10 2017-02-16 H. Lee Moffitt Cancer Center And Research Institute, Inc. Enhanced Expansion of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy
US10166255B2 (en) 2015-07-31 2019-01-01 Regents Of The University Of Minnesota Intracellular genomic transplant and methods of therapy
EP3228701A1 (en) * 2016-04-05 2017-10-11 Fundación Centro Nacional de Investigaciones Oncológicas Carlos III Method for preparing lymphocytes capable of infiltrating a solid tumor, lymphocytes obtainable by said method and uses thereof
AU2017292889A1 (en) 2016-07-07 2019-02-14 Iovance Biotherapeutics, Inc. Programmed death 1 Ligand 1 (PD-L1) binding proteins and methods of use thereof
GB2605540B (en) 2016-10-18 2022-12-21 Univ Minnesota Tumor infiltrating lymphocytes and methods of therapy
MX2019004707A (es) 2016-10-26 2019-08-12 Iovance Biotherapeutics Inc Reestimulacion de linfocitos infiltrantes de tumor crioconservados.
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
MX2019005617A (es) 2016-11-17 2019-08-14 Iovance Biotherapeutics Inc Linfocitos infiltrantes de tumores remanentes y metodos de preparacion y uso de los mismos.
WO2018129336A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
AU2018227810A1 (en) * 2017-03-01 2019-08-29 Nektar Therapeutics Immunotherapeutic tumor treatment method using an interleukin-2 receptor alpha, beta-selective agonist in combination with adoptive cell transfer therapy
JOP20190224A1 (ar) 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
US11254913B1 (en) 2017-03-29 2022-02-22 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
CN110662762A (zh) 2017-05-24 2020-01-07 诺华股份有限公司 抗体细胞因子移植蛋白和用于治疗癌症的方法
WO2018226714A1 (en) * 2017-06-05 2018-12-13 Iovance Biotherapeutics, Inc. Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
CN111511375A (zh) 2017-06-30 2020-08-07 因提玛生物科学公司 用于基因治疗的腺相关病毒载体
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
GB201801067D0 (en) * 2018-01-23 2018-03-07 Price Nicola Kaye Biomarkers predictive of tumour infiltrating lymphocyte therapy and uses thereof
BR112020018658A2 (pt) 2018-03-15 2020-12-29 KSQ Therapeutics, Inc. Composições de regulação gênica e métodos para imu-noterapia aprimorada
WO2019210131A1 (en) 2018-04-27 2019-10-31 Iovance Biotherapeutics, Inc. Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
CN108486120B (zh) * 2018-04-28 2019-12-06 新乡医学院 一种新型CpG ODN序列及其在抗黑色素瘤上的应用
GB201911066D0 (en) 2019-08-02 2019-09-18 Achilles Therapeutics Ltd T cell therapy
CA3176356A1 (en) 2020-04-22 2021-10-28 Anne BROOKS Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
IL297594A (en) 2020-04-28 2022-12-01 Achilles Therapeutics Uk Ltd t cell therapy
EP4237566A2 (en) * 2020-10-27 2023-09-06 H. Lee Moffitt Cancer Center & Research Institute, Inc. Oncolytic virus boosts t cell response for effective til therapy
GB202109886D0 (en) 2021-07-08 2021-08-25 Achilles Therapeutics Uk Ltd Assay
EP4320435A1 (en) 2021-04-09 2024-02-14 Achilles Therapeutics UK Limited Batch release assay for pharmaceutical products relating to t cell therapies
IL309200A (en) 2021-06-22 2024-02-01 Achilles Therapeutics Uk Ltd A method for producing antigen-specific T cells
US20230270784A1 (en) * 2021-12-07 2023-08-31 Memgen, Inc. Oncolytic virus boosts t cell response for effective til therapy
WO2023201369A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5331573A (en) 1990-12-14 1994-07-19 Balaji Vitukudi N Method of design of compounds that mimic conformational features of selected peptides
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US5631280A (en) 1995-03-29 1997-05-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5811515A (en) 1995-06-12 1998-09-22 California Institute Of Technology Synthesis of conformationally restricted amino acids, peptides, and peptidomimetics by catalytic ring closing metathesis
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
ES2437567T3 (es) 2003-11-05 2014-01-13 Dana-Farber Cancer Institute, Inc. Péptidos alfa helicoidales estabilizados y utilizaciones de los mismos
US7858743B2 (en) * 2004-09-09 2010-12-28 Ludwig Institute For Cancer Research SSX-4 peptides presented by HLA class II molecules
PT2327763T (pt) * 2005-08-05 2018-05-11 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh Geração de células t específicas de antigénios
WO2007071389A1 (en) * 2005-12-21 2007-06-28 Sentoclone Ab Method for treating disseminated cancer
JP5631201B2 (ja) 2007-03-28 2014-11-26 プレジデント アンド フェローズ オブ ハーバード カレッジ ステッチングされたポリペプチド
EP3375868A1 (en) 2007-11-08 2018-09-19 Dana Farber Cancer Institute, Inc. Stimulation of anti-tumor immunity using dendritic cell/tumor cell fusions and anti-cd3/cd28
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
KR20120093978A (ko) * 2009-10-27 2012-08-23 이뮤니쿰 에이비 항원 특이적 ｔ 세포의 증식 방법
WO2012127464A2 (en) * 2011-03-23 2012-09-27 Gavish-Galilee Bio Applications Ltd Constitutively activated t cells for use in adoptive cell therapy
WO2013192628A1 (en) 2012-06-22 2013-12-27 University Of South Florida Peptoid-peptide hybrids and their use
CN103243072B (zh) * 2013-05-09 2016-03-02 杭州中赢生物医疗科技有限公司 CD8α-白介素21片段-CD137复合物扩增激活淋巴细胞的方法
CN103396992A (zh) * 2013-08-15 2013-11-20 中国人民解放军第二军医大学 寡克隆肝癌肿瘤浸润淋巴细胞的培养和应用
CN103520198B (zh) * 2013-09-24 2016-01-20 彭光勇 一种制备用于阻止肿瘤细胞诱导t细胞老化并逆转其免疫抑制能力的药物的方法及其在抗肿瘤免疫治疗中的用途
CN106659913A (zh) * 2014-03-20 2017-05-10 H.李莫菲特癌症中心研究院 用于过继细胞疗法的肿瘤浸润淋巴细胞

Also Published As

Publication number Publication date
EP3119477B1 (en) 2020-01-01
CN112080467A (zh) 2020-12-15
BR112016021370A2 (pt) 2017-08-15
US20190177693A1 (en) 2019-06-13
AU2015231041B2 (en) 2020-07-16
JP2023123877A (ja) 2023-09-05
EP3698850A1 (en) 2020-08-26
CA2943389A1 (en) 2015-09-24
EP3119477A1 (en) 2017-01-25
EA036386B1 (ru) 2020-11-03
AU2015231041A1 (en) 2016-11-03
US20170081635A1 (en) 2017-03-23
ES2776407T3 (es) 2020-07-30
US11518980B2 (en) 2022-12-06
US20220282215A1 (en) 2022-09-08
EP3119477A4 (en) 2018-03-07
KR20230085225A (ko) 2023-06-13
JP2017511375A (ja) 2017-04-20
WO2015143328A1 (en) 2015-09-24
AU2023200308A1 (en) 2023-03-02
BR112016021370A8 (pt) 2021-07-20
CA2943389C (en) 2023-10-31
KR20160146713A (ko) 2016-12-21
JP2020182477A (ja) 2020-11-12
MX2020005634A (es) 2020-08-20
AU2020256412A1 (en) 2020-11-26
CN106659913A (zh) 2017-05-10
EA201691866A1 (ru) 2017-01-30

Similar Documents

Publication Publication Date Title
MX2020005634A (es) Composiciones y metodos para mejorar los linfocitos infiltrantes de tumor para terapia celular adoptiva.
GB2557123A (en) Modified cells and methods of therapy
MX2017012206A (es) Proliferacion ex vivo de celulas epiteliales.
NZ731467A (en) Anti-tim3 antibodies and methods of use
PH12017500803A1 (en) Anti-pd-1 antibodies
MX2018010473A (es) Terapia de combinacion con anticuerpos anti cumulo de diferenciacion 73 (cd73).
TW201613648A (en) Compounds and compositions for immunotherapy
MX2021006734A (es) Metodo para tratar el cancer.
GB201510771D0 (en) Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer
MX2018003532A (es) Conjugados de afinidad-oligonucleotido y usos de los mismos.
HK1253531A1 (zh) 用於免疫治療的新型肽和肽組合物以及用於胰腺癌和其他癌症的支架產生方法
MX2019003616A (es) Celulas beta derivadas de celulas madre (sc-beta) y composiciones y metodos para generarlas.
GB2570593A (en) Methods relating to intestinal organ-on-a-chip
MY189857A (en) Methods of selecting t cell line and donor thereof for adoptive cellular therapy
MX2017014735A (es) Metilacion de promotor pd-l1 en cancer.
MX2018002344A (es) Metodo para tratar el cancer.
TW201612308A (en) Collector architecture layout design
MX2015013177A (es) Combinacion de tratamientod de cancer usando microarns e inhibidores de egfr-tki.
MX2017006015A (es) Composiciones para usar en el tratamiento de cancer renal.
PH12016501422A1 (en) Functionalised benzopyran compounds and use thereof
PH12018502303A1 (en) Compositions and methods for bioengineered tissues
HUE047540T2 (hu) Javított allogén dendritikus sejtek rák kezelésében történõ alkalmazásra
EP3645020A4 (en) COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY
EP3645561A4 (en) COMPOSITIONS AND METHODS OF ADOPTIVE CELL THERAPY AGAINST CANCER
NZ744131A (en) Tumor-infiltrating lymphocytes for adoptive cell therapy

Legal Events

Date Code Title Description
FG Grant or registration